Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryosuke Tanino has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cross-Organ Differences Between IL-4Rα Blockade and IL-13-Selective Therapy in Immune-Priming and Barrier-Effector Compartments: Implications for Skin, Airway, and Gastrointestinal Diseases

    by Ryosuke Tanino, Takayoshi Komatsu-Fujii

    Antibody therapies targeting the IL-4/IL-13 axis are used in type 2 inflammatory diseases affecting skin, airways, and gastrointestinal tissues. Clinical responses and biomarker behavior differ across organs, complicating trial interpretation and endpoint selection. We propose an IL-4Rα-centered framework that relates these differences to receptor-responsive cells, local cytokine supply, and the compartments sampled by each endpoint. Type I receptors (IL-4Rα/γc) support IL-4-dependent immune priming, including type 2 helper T-cell (Th2) differentiation and immunoglobulin E (IgE) class switching. Type II receptors (IL-4Rα/IL-13Rα1) respond to both IL-4 and IL-13 and are prominent in epithelial and mesenchymal effector programs. Selected immune populations also respond through Type II receptors. We connect receptor biology to organ-specific experimental mechanisms and clinical outcomes, distinguish within-cell receptor expression from tissue cellular composition, and consider IL-13Rα2 as a separate ligand-buffering regulator. These assignments are predominant tendencies rather than exclusive cellular localizations or validated treatment-selection rules. This approach links molecular, tissue, and clinical endpoints while avoiding claims of drug superiority based on cross-trial comparisons.

  • Open Access

    Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR ‐Mutated NSCLC

    by Kento Kono, Ryosuke Tanino, Yukari Tsubata, Eshat Fahmida Haque, Takeshi Isobe, Tamio Okimoto

    The current standard postoperative adjuvant therapy for patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) includes chemotherapy, including microtubule inhibitors prior to the administration of osimertinib, an EGFR‐tyrosine kinase inhibitor (TKI). However, multidrug resistance following treatment with microtubule inhibitors has been reported, and the optimal sequence of drug administration for EGFR‐mutated NSCLC remains undefined. In this study, we investigated whether prior treatment with microtubule inhibitors induces acquired cross‐resistance to osimertinib in EGFR‐mutated NSCLC cells in vitro. To model acquired resistance, PC‐9 cells were exposed to vinorelbine or paclitaxel for 18 weeks—approximating the clinical duration of four adjuvant chemotherapy cycles—and subsequent drug sensitivity and signaling pathway alterations were assessed using cell viability assays, RNA sequencing, and immunoblotting. We found that two human NSCLC cell lines derived from PC‐9 exhibited reduced sensitivity to osimertinib after 18 weeks of in vitro treatment with tubulin inhibitors: vinorelbine (PC‐9/VNR) and paclitaxel (PC‐9/PTX). Furthermore, PC‐9/VNR and PC‐9/PTX cells showed activation of FZD7 and calcium/calmodulin‐dependent protein kinase II (CaMKII), along with increased sensitivity to the CaMKII inhibitor KN‐93, which exerted additive or synergistic effects. These findings suggest that CaMKII plays a critical role in EGFR‐TKI resistance. This study underscores the importance of optimizing the timing of EGFR‐TKI administration in the therapeutic sequence for EGFR‐mutated NSCLC.


  • Open Access

    Bronchial Physiological Saline Injection to Visualize Peripheral Pulmonary Lesions in Ultrathin Bronchoscopy

    by Mika Nakao, Tamio Okimoto, Noriaki Kurimoto, Ryosuke Tanino, Misato Kobayashi, Kazuhisa Nakashima, Takamasa Hotta, Yukari Tsubata, Takeshi Isobe

    Background: During bronchial lavage, the lumen can be viewed better by injecting physiological saline into the bronchus. This study aimed to investigate the effect of injecting physiological saline into the bronchus while directly observing the bronchial lumen with peripheral pulmonary lesions using an ultrathin bronchoscope. Methods: We evaluated changes in the depth of field and signal-to-noise ratio due to saline immersion in bronchoscopic images captured with line patterns. We injected physiological saline through the working channel into the bronchial lumen and directly observed the lesions (mainly in cases of suspected peripheral lung cancer) in 38 patients using white-light and narrow-band imaging. Ultrathin bronchoscopic findings and histopathological diagnoses were analyzed. Results: Saline immersion extended the range of subject distance within the depth of the field with an improved signal-to-noise ratio. Saline immersion elevated the signal-to-noise ratio and increased the highest signal-to-noise ratio in the white-light images from 3.12 dB to 3.77 dB (1.21-fold). Under narrow-band imaging, saline immersion also increased the highest signal-to-noise ratio from 5.18 dB to 6.44 dB (1.24-fold). We were able to directly observe the bronchial lumen of the peripheral lesions in 30/38 cases (78.9%). Three (60%) of the five squamous cell carcinomas were of the epithelial type, and 12 (92%) of the 13 adenocarcinomas, including peripheral pulmonary lesions, were of the subepithelial type, similar to central lesions. Conclusions: Injecting saline into the peripheral bronchus is useful for direct bronchoscopic evaluation of peripheral lesions.


  • Open Access

    Predictive value of Eastern Cooperative Oncology Group performance status and body mass index for antifibrotic tolerability and prognosis in patients with idiopathic pulmonary fibrosis

    by Hirotoki Tsuda, Ryosuke Tanino, Tamio Okimoto, Sayaka Ueno, Takuya Tanimoto, Yukari Tsubata, Nobuhisa Ishikawa, Takeshi Isobe


  • Open Access

    Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells

    by Hitoshi Kotani, Wei Han, Yuichi Iida, Ryosuke Tanino, Kazuaki Katakawa, Tamio Okimoto, Yukari Tsubata, Takeshi Isobe, Mamoru Harada

    Background: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high specificity for vascular endothelial growth factor receptors (VEGFRs). Aim: We determined whether axitinib could induce senescence in human cancer cells and be lysed by the senolytic drug ABT-263. Methods: Human lung and breast adenocarcinoma cell lines were used. These cells were cultured with axitinib or a multi-target TKI lenvatinib. The expression of β-galactosidase, VEGFRs, Ki-67, reactive oxygen species (ROS) of cancer cells, and their BrdU uptake were evaluated by flow cytometry. The mRNA expression of p21 and IL-8 was examined by quantitative PCR. The effects of TKIs on phosphorylation of Akt and Erk1/2, as downstream molecules of VEGFR signaling, were examined by immunoblot. The in vivo anti-cancer effect was examined using a xenograft mice model. Results: Axitinib, but not lenvatinib, induced cellular senescence (increased cell size and enhanced expression of β-galactosidase) in all adenocarcinoma cell lines. Axitinib-induced senescence was unrelated to the expression of VEGFRs on cancer cells. ROS were involved in axitinib-induced senescence. Axitinib-induced senescent lung adenocarcinoma A549 cells were drastically lysed by ABT-263. In A549-xenografted mice, combination therapy with axitinib and ABT-263 significantly suppressed tumor growth with the induction of apoptotic cancer cells.


  • Open Access

    Hypoxia‐related carbonic anhydrase 9 induces serpinB9 expression in cancer cells and apoptosis in T cells via acidosis

    by Mamoru Harada, Hitoshi Kotani, Yuichi Iida, Ryosuke Tanino, Takafumi Minami, Yoshihiro Komohara, Kazuhiro Yoshikawa, Hirotsugu Uemura

    Hypoxia is a common feature of solid tumors. However, the impact of hypoxia on immune cells within tumor environments remains underexplored. Carbonic anhydrase 9 (CA9) is a hypoxia‐responsive tumor‐associated enzyme. We previously noted that regardless of human CA9 (hCA9) expression, hCA9‐expressing mouse renal cell carcinoma RENCA (RENCA/hCA9) presented as a “cold” tumor in syngeneic aged mice. This study delves into the mechanisms behind this observation. Gene microarray analyses showed that RENCA/hCA9 cells exhibited elevated mouse serpinB9, an inhibitor of granzyme B, relative to RENCA cells. Corroborating this, RENCA/hCA9 cells displayed heightened resistance to antigen‐specific cytotoxic T cells compared with RENCA cells. Notably, siRNA‐mediated serpinB9 knockdown reclaimed this sensitivity. In vivo tests showed that serpinB9 inhibitor administration slowed RENCA tumor growth, but this effect was reduced in RENCA/hCA9 tumors, even with adjunctive immune checkpoint blockade therapy. Further, inducing hypoxia or introducing the mouse CA9 gene upregulated serpinB9 expression, and siRNA‐mediated knockdown of the mouse CA9 gene inhibited the hypoxia‐induced induction of serpinB9 in the original RENCA cells. Supernatants from RENCA/hCA9 cultures had lower pH than those from RENCA, suggesting acidosis. This acidity enhanced serpinB9 expression and T cell apoptosis. Moreover, coculturing with RENCA/hCA9 cells more actively prompted T cell apoptosis than with RENCA cells. Collectively, these findings suggest hypoxia‐associated CA9 not only boosts serpinB9 in cancer cells but also synergistically intensifies T cell apoptosis via acidosis, characterizing RENCA/hCA9 tumors as “cold.”


  • Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration‐induced nephropathy

    by Yuki Mitarai, Ryosuke Tanino, Kazuhisa Nakashima, Takamasa Hotta, Takeshi Isobe, Yukari Tsubata

    AimsLong-term administration of pemetrexed (PEM) in patients with lung cancer can cause renal damage, leading to treatment discontinuation. Previous reports have suggested that specific single nucleotide polymorphisms (SNPs) in the folylpolyglutamate synthase (FPGS) gene affect therapeutic efficacy; however, whether the FPGS SNPs affect renal function is unclear. Identifying SNPs related to renal damage during PEM administration may help predict the decrease in renal function caused by PEM. MethodsWe retrospectively examined age, sex, body weight, total administered PEM, combined platinum, estimated glomerular filtration rate (eGFR) and serum creatinine (SCr) levels before and after PEM administration in patients with non-small cell lung cancer and searched for the alleles of FPGS SNPs (rs1544105 and rs10106) using DNA extracted from whole blood samples of patients. ResultsRenal function decreased after PEM administration in 26 cases overall. The SCr and eGFR indices showed decreased renal function irrespective of concomitant cisplatin use. Based on promoter activity and miRNA binding predictions, rs1544105-C and rs10106-T were hypothesized to increase FPGS expression. Single SNP analyses showed no significant differences in renal function between groups with and without each SNP. Multiple regression analysis revealed that the most significant factors for decreased renal function were sex on SCr and the number of SNPs on eGFR. In subgroup analyses, the patients with rs10106-T showed a decline in renal function in the older group. ConclusionsThe number of FPGS SNPs may contribute to PEM-induced renal impairment. Detecting FPGS SNPs may help predict PEM-induced renal damage.

  • Open Access

    Data from Anticancer Activity of ZnO Nanoparticles against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model

    by Ryosuke Tanino, Yoshihiro Amano, Xuexia Tong, Rong Sun, Yukari Tsubata, Mamoru Harada, Yasuhisa Fujita, Takeshi Isobe

    Small-cell lung cancer, a highly malignant form of lung cancer, often responds to first-line treatments but relapses in most cases with resistance to further treatments. We tested zinc oxide (ZnO) nanoparticles against small-cell lung cancer and other cancer cell lines, in light of reported anticancer effects in vitro. Because of a strong safety record, ZnO nanoparticles are frequently used in biomedical research, including in cellular imaging and drug delivery, and have been used for many years in several commercial products such as skin care agents. Strikingly, ZnO nanoparticles were genotoxic against small-cell lung cancer cells, resulting in low viability, even in cells orthotopically grafted onto mouse models. However, the nanoparticles were less cytotoxic against normal lung–derived cells and did not elicit observable adverse effects after intravenous administration. ZnO nanoparticles were also found to induce highly reactive oxygen species and DNA leakage from nuclei. This study is the first comprehensive evaluation of the anticancer effects of ZnO nanoparticles in vitro and in vivo and highlights new therapeutic opportunities against small-cell lung cancer.

  • Open Access

    Supplementary Figures S1-S6 and Supplementary Table S1 from Anticancer Activity of ZnO Nanoparticles against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model

    by Ryosuke Tanino, Yoshihiro Amano, Xuexia Tong, Rong Sun, Yukari Tsubata, Mamoru Harada, Yasuhisa Fujita, Takeshi Isobe

    Supplementary Figure S1 - Evaluation of other batches of ZnO nanoparticles (ZnO_71.9). Supplementary Figure S2 - Background level of fluorescence of N417, H82, OUS-11, and BEAS-2B cells treated with 25 μM Zinquin ethyl ester. Supplementary Figure S3 - The comparison of gene expression in antioxidants between small-cell lung cancer (SCLC) and normal cells. Supplementary Figure S4 - Data of ZnO-treated mouse after orthotopically injection. Supplementary Figure S5 - Tumor metastasis in vehicle-treated mice after N417 orthotopically injection. Supplementary Figure S6 - Schematic illustration of ROS productions induced by ZnO nanoparticles. Supplementary Table S1 -The sequences for primers used in quantitative PCR.

  • Open Access

    Data from Anticancer Activity of ZnO Nanoparticles against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model

    by Ryosuke Tanino, Yoshihiro Amano, Xuexia Tong, Rong Sun, Yukari Tsubata, Mamoru Harada, Yasuhisa Fujita, Takeshi Isobe

    Small-cell lung cancer, a highly malignant form of lung cancer, often responds to first-line treatments but relapses in most cases with resistance to further treatments. We tested zinc oxide (ZnO) nanoparticles against small-cell lung cancer and other cancer cell lines, in light of reported anticancer effects in vitro. Because of a strong safety record, ZnO nanoparticles are frequently used in biomedical research, including in cellular imaging and drug delivery, and have been used for many years in several commercial products such as skin care agents. Strikingly, ZnO nanoparticles were genotoxic against small-cell lung cancer cells, resulting in low viability, even in cells orthotopically grafted onto mouse models. However, the nanoparticles were less cytotoxic against normal lung–derived cells and did not elicit observable adverse effects after intravenous administration. ZnO nanoparticles were also found to induce highly reactive oxygen species and DNA leakage from nuclei. This study is the first comprehensive evaluation of the anticancer effects of ZnO nanoparticles in vitro and in vivo and highlights new therapeutic opportunities against small-cell lung cancer.